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Abstract. A mouse mastocytoma model was used to de- 
termine the biodistribution and tumour uptake of four ra- 
diopharmaceuticals developed to target the serotonin 
synthetic pathway in carcinoid tumours. Three of the 
compounds were competitive inhibitors of the rate-limit- 
ing enzyme of serotonin synthesis, tryptophan hydroxyl- 
ase. Radiolabelled iodo-DL-phenylalanine (iodine-131 
PIPA) was found to have the highest uptake and turnout- 
to-liver ratio. Four patients with known carcinoid tu- 
mours were then injected with 0.5 mCi 131I-PIPA and 
imaged at 1, 4, 24 and 48 h post-injection. The radio- 
pharmaceutical, however, failed to localize in the known 
turnout sites. This result was in contrast to the authors' 
experience of 131I- and 123I-MIBG imaging of carcinoid 
turnouts. Seven patients with known metastatic carcinoid 
tumours, two patients with symptoms of recurrence fol- 
lowing tumour resection, one patient with completely re- 
sected disease, and two patients with a flushing syn- 
drome of uncertain aetiology were studied with ~3tI- 
MIBG. Three of the seven patients with known metastat- 
ic disease had positive 131I-MIBG scans. Both patients 
with clinical evidence of recurrent disease had negative 
scans, as did the patient who was considered to have had 
complete resection of her primary tumour. The two pa- 
tients with idiopathic flushing syndrome also had nega- 
tive scans. Among seven patients imaged with 123I- 
MIBG there were four true-negative scans and one false- 
negative, the latter in a patient with biochemical and CT 
evidence of recurrence. In a seventh patient with distant 
metastases there was variable uptake in some of the le- 
sions. Four patients were studied with indium-Ill  pen- 
etetreodide. Two patients with metastatic carcinoid dis- 
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ease had positive scans, although hepatic metastases 
were not seen in one. Another two with idiopathic flush- 
ing syndrome had normal studies. The literature suggests 
that up 50% of carcinoid tumour cases are detected with 
131I-MIBG, compared to a sensitivity of 87% reported 
with somatostatin receptor imaging using 111In-pent- 
etreotide. The experience with 123I-MIBG is much less 
extensive. The mechanisms of carcinoid tumour local- 
ization for each of the three classes of radiotracers are 
discussed and contrasted to their varying sensitivities. 
The relative success of 131I-MIBG and 111In-pentetreo- 
tide relative to ~31I-PIPA may be related to the fact that 
131I-MIBG is actively taken up and stored by the entero- 
chromaffin cells of the turnouts and ~11In-pentetreotide 
binds to cell surface receptors, whereas 13q-PIPA binds 
to tryptophan hydroxylase, which may be present in 
quantities too small to permit tumours to be imaged. 
Key words: Carcinoid - Radionuclide imaging - Phenyl- 
alanine - Metaiodobenzylguanidine - Pentetreotide - 
Iodophenylalanine 
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Introduction 
Carcinoid tumours are derived from the enterochromaf- 
fin cells of the gastrointestinal tract. They are considered 
to be neuroectodermal derivatives forming part of the 
APUD series of tumours. These tumours may produce a 
number of vasoactive amines and peptides which play a 
role in the development of the carc~noid syndrome. 
These substances include serotonin (5-hydroxytrypta- 
mine), prostaglandins, substance R kallikrein, histamine, 
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Fig. 1. Diagrammatic illustration of serotonin metabolism, high- 
lighting points of action of various scintigraphic agents for carci- 
noid imaging (5HTP 5-hydroxytryptophan, 5HT 5-hydroxytrypta- 
mine (serotonin), 5HIAA 5-hydroxyindoleacetic acid, PIPA p- 
iodophenylalanine, MIBG meta-iodobenzylguanidine). Note that 
there are believed to be at least five subtypes of somatostatin re- 
ceptors 
dopamine and neuropeptide K [1, 2]. As serotonin is 
synthesized in large quantities within these tumours, this 
unique synthetic pathway is an obvious target for com- 
pounds designed to selectively localize in carcinoids. 
The serotonin biosynthetic pathway involves two en- 
zymatic steps (Fig. 1). Tryptophan 5-hydroxylase cata- 
lyses the hydroxylation of tryptophan to 5-hydroxytryp- 
tophan (5-HTP) and 5-HTP decarboxylase (dopa decar- 
boxylase) catalyses the decarboxylation of 5-HTP to 5- 
hydroxytryptamine. Competitive inhibitors of the rate- 
limiting enzyme, tryptophan-5-hydroxylase, have been 
shown to at least partially alleviate the carcinoid syn- 
drome in a number of cases [3, 4]. For this reason, radio- 
labelled inhibitors of this enzyme have been considered 
as potential agents for the imaging of carcinoid tumours. 
Costella used iodine-131 5-iodotryptophan in two pa- 
tients with known metastatic carcinoid disease, with liv- 
er metastases being visualized in one [5]. 
Serotonin is stored in cytoplasmic membrane-bound- 
ed vesicles following synthesis (see Fig. 1). The vesicu- 
lar contents are discharged following depolarization of 
the cell membrane by rapid sodium and slow calcium 
currents which cause fusion of the vesicular membrane 
with the cell membrane and exocytosis of the vesicle 
contents. Many ceils of the APUD series, including car- 
cinoids, have a type 1 biogenic amine active reuptake 
mechanism by which extracellular amines are concen- 
trated across the cell membrane into the cytoplasm. The 
radiopharmaceutical metaiodobenzylguanidine (MIBG) 
exploits this mechanism to image a wide range of neuro- 
endocrine tumours. The largest experience has been with 
phaeochromocytomas and neuroblastomas, although car- 
cinoids have also been successfully imaged [6]. 
The inhibition of carcinoid secretory activity by so- 
matostatin and its analogues is a well-established phe- 
nomenon [7]. Autoradiography of tissue specimens from 
carcinoid tumours has demonstrated expression of so- 
matostatin tissue receptors (SSTRs) in approximately 
87% of cases [8]. These receptors are widely distributed 
in tissues of neuroendocrine origin as well as in brain, 
kidney and lymphocytes. In some cell lines receptor ex- 
pression is inversely related to tumour differentiation 
[91. Long-acting somatostatin analogues labelled with 
iodine-123 and more recently indium-Ill  have proven 
to be practical agents for the in vivo visualization of car- 
cinoid and many other somatostatin receptor-positive tu- 
mours [6]. 
The main purpose of this study was to investigate the 
use of radiolabelled tryptophan hydroxylase inhibitors as 
potential radiopharmaceuticals for the imaging of carci- 
noid tumours. The study design comprised two phases. 
Firstly, a number of tryptophan hydroxylase inhibitors 
were synthesized, radiolabelled and administered to ani- 
mals bearing a serotonin-synthesizing tumour in order to 
determine the tissue distribution and toxicity of these 
compounds. Following this, using the compound with 
the best target-to-background ratio in the animal model, 
an attempt was made to image known carcinoid tumours 
in four patients. We also compare and contrast this ap- 
proach with our experience and those of others using 
13tI- and 123I-MIBG and 111in pentetreotide to image car- 
cinoid tumours. 
Study design and results 
Materials and methods: phase 1 
Radiolabelled serotonergic agents of two general classes 
were prepared and tested. Three radiolabelled trypto- 
phan hydroxylase inhibitors were synthesized: 5-iodo- 
tryptophan (125I-5-ITP), 6-iodotryptophan (12sI-6-ITP), 
131I-p-iodo-DL-phenylalanine (131I-PIPA) and 1~5I-p- 
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iodo-DL-phenylalanine (]25I-PIPA). Meta-4-iodoamphet- 
amine (~25I-PIA), a compound directly toxic to trypto- 
phan hydroxylase-secreting cells of the brain, was also 
synthesized. 
The ]25I-iodotryptophans were produced by ex- 
change-labelling the corresponding 127I compounds un- 
der aqueous conditions. Radiochemical yields of up to 
70% and specific activities (determined by ultraviolet 
spectroscopy) of 0.3 and 0.5 mCi/gmol were obtained 
[10], The 127I iodotryptophans were synthesized by 
Mangner et al. from their respective nitroindoles by a 
seven-step sequence modified from the procedure of 
Lambrecht et al. for overall yields of 20%-25% [11]. 
The "cold" iodoamphetamine was prepared by a three- 
step sequence from 4-iodobenzaldehyde and then radio- 
labelled by exchange in a melt [10]. 
For tissue distribution studies, a mouse mastocytoma 
model (LAF-1 mastocytoma, Mason Research Institute, 
Worcester, Mass.) was chosen. The mouse mastocytoma 
is a solid, rapidly growing tumour which, like the carci- 
noid tumour, produces substantial quantities of serotonin 
[12, 13]. In addition, the biochemical properties of tryp- 
tophan hydroxylase isolated from this type of neoplasm 
have been reported to be very similar to those isolated 
from carcinoid tumours [14, 15]. Unlike the preliminary 
studies for the development of adrenal sympathomedul- 
lary tumour imaging agents, in which the normal adrenal 
medulla served as an experimental target organ, the de- 
velopment of an agent for the imaging for carcinoid tu- 
rnouts has been hampered by the fact that enterochro- 
maffin cells are not concentrated into a focal organ but 
rather form a diffuse system distributed throughout the 
body. It was therefore necessary to use the animal tu- 
mour model described above for tissue distribution stud- 
ies. 
The turnouts were implanted in 15 LAF-1 mice (25 g) 
and grown for 13 days. Three LAF-1 mice per com- 
pound per time interval were injected with each of the 
125I compounds and tissue distribution of these com- 
pounds was determined at 1.5 h and 4 h post intraperito- 
neal injection of 26 gCi of the radiopharmaceutical. The 
specific activities of the radiopharmaceuticals tested 
were: 5-iodotryptophan: 0.67mCi/mg; 6-iodotrypto- 
phan: 0.16 mCi/mg; 4-iodophenylalanine: 0.44 mCi/mg; 
and 4-iodoamphetamine: 0.85 mCi/mg. 
Results: phase I 
Uptake of the radiopharmaceutical compounds was mea- 
sured in the tumour, liver, thyroid, pancreas, intestine, 
muscle and blood (Table 1). From these data it can be 
seen that although each of these compounds localized 
selectively in the mastocytoma, the best uptake (0.23% 
kg dose/g) and tumour-to-liver ratios (5.5) were obtained 
with ~25I-PIPA. On the basis of these results radioiodi- 
nated PIPA was selected for further study as a tumonr 
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laSI-labelled compounds are unsuited to in vivo scintig- 
raphy it was decided to use ~31I-PIPA in the human stud- 
ies. 
Materials and methods: phase II 
131I-PIPA was prepared using the method detail above. 
Thin-layer chromatography of the product was per- 
formed. A sample of the product was dissolved in an 
acetate buffer with 1% benzyl alcohol, and thin-layer 
chromatography performed using thin-layer silica gel 
(K6F) with both EtOH:EtOAc:NH4OH(20:20:I) and 
BuOH:AcOH:H20 (5:2:1) solvent systems. No free 1311 
as iodide was detected. 
Acute toxicity studies were carried out by administer- 
ing 5 mg/kg PIPA to five rats and two mg/kg PIPA to 
three dogs. A matched control group was selected for 
each species. No drugs were administered to the control 
groups. No adverse reactions or deaths were observed in 
any group over a 5-day observation period. The animals 
were then sacrificed and samples of ovary, liver, small 
and large intestine, spleen, lung and pancreas from sub- 
jects in experimental and control groups were submitted 
for histological examination. No specific drug-related 
histopathological alterations were seen in specimens 
from control or experimental animals of either species. 
Although no toxicity data were available in humans 
for 131I-PIPA, reports documenting the use of the chlori- 
nated analogue, parachlorophenylalanine, in the treat- 
ment of carcinoid syndrome describe dose-related side- 
effects only at doses greater than 2 g [3, 16]. 
MIRD formalism was used in the calculation of the 
radiation dosimetry of 131I-PIPA using biodistribution 
data derived from rats and the assumption that the do- 
simetry in humans would parallel that in the rats [16]. 
Organ activity-concentration in rats administered 100 
gCi 131I-PIPA was calculated using an ionization cham- 
ber. Table 2 summarizes the results for the dosimetric 
calculations. 
Four patients with known metastatic carcinoid tu- 
mours were studied. All four patients had extensive 
metastatic involvement of the liver. Three of the patients 
had primary small bowel tumours and in one patient the 
site of the primary tumour was unknown (Table 3). 
The patients were injected with 0.50-0.53 mCi 1311- 
PIPA, corresponding to approximately 0.1 mg of PIPA 
or 1.4-5.7 mg/kg, a dose well within the reported safety 
limits for p-chlorophenylalanine and representing a safe- 
ty margin exceeding 350:1 based on our acute toxicity 
studies [3, 5]. All patients received one drop of saturated 
solution of potassium iodide (38 mg iodide) 3 times dai- 
ly starting 24 h prior to and continuing for 48 h after 
tracer administration to achieve thyroid blockade. Urine, 
faeces and blood were sampled at intervals over a 48-h 
period. Subjects were scanned at 0-1 h, 4 h, 24 h and 
48 h post-injection using a wide-field-of-view gamma 
camera (Pho Gamma) fitted with a high-energy, parallel- 
Table 2. Estimated internal radiation dose/0.5 mCi 13 q_PiPA a 









Small intestine wall 0.51 
Large intestine wall 0.53 
Thyroid (unblocked) 33.7 
Thyroid (blocked) 3.37 
Total body 0.32 
a Based on biodistribution in rats and using MIRD formalism 
hole collimator. Overlapping planar images of 20 min 
duration were acquired of the trunk in a 64x64 matrix. 
Results: phase II 
Excretion and blood activity data for 131I-PIPA are sum- 
marized in Table 3, which demonstrates that the majority 
of activity is excreted via the urine and very little in the 
faeces. In all four patients studied the 131I-PIPA failed to 
localize at sites of known tumour involvement. The hu- 
man scintigraphic biodistribution of 131I-PIPA is depict- 
ed in Fig. 2. 
Materials and methods: I31I and I23I-MIBG studies 
Since 1984, we have performed 131I-MIBG scintigraphy 
on 12 patients with confirmed or suspected carcinoid tu- 
mour, and six other patients were studied with 1231- 
MIBG. Our experience with ten of these patients was re- 
ported previously [17]. The salient clinical features are 
summarized inTable 4. Of the 18 patients, six had histo- 
logically proven metastatic disease and one an unresect- 
ed primary lesion, two patients had clinical symptoms 
highly suggestive of metastatic spread following resec- 
tion of the primary tumour, and one patient had had the 
primary tumour completely excised with no evidence of 
local or distant disease at the time of imaging. The re- 
maining five patients had an idiopathic flushing syn- 
drome without radiological or conclusive biochemical 
evidence of carcinoid tumour. A prolonged interval be- 
tween the trials with 131I-PIPA and 131I- and 123I-MIBG 
precluded the same patients being studied with both 
agents. Six patients were studied with 123I-MIBG: three 
with idiopathic flushing syndrome, one with a resected 
single primary, and one patient each with local and dis- 
tant metastases (Table 4). 
Each patient was administered 0.5 mCi 131I-MIBG 
(specific activity 2.9-3.6 mCi/mg) intravenously and im- 
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Table 3. Clinical data, serum clearance and 
excretion data in patients following injec- 
tion with 131I-PIPA 
Patient 1 2 3 4 
Age (years) 54 58 35 
Primary Small bowel Ileum Jejunum 
tumour 







Urine 0-3 h 
% Dose/g 0.0384 0.0345 0.0275 0.0529 
% Dose 16,68 - - 5.13 
Urine 6-12 h 
% Dose/g 0.0107 0.0132 0.0173 0.0381 
% Dose 7.52 - 4.95 
Urine 24-48 h 
% Dose/g 0.0041 0.0056 0.0061 0.0058 
% Dose 5.79 - - 12.51 
Faeces 0-24 h 
% Dose/g 0.0005 0.0022 0.0001 0.0010 
% Dose 0.091 - - 0.099 
Faeces 24-48 h 
% Dose/g 0.0006 0.0012 0.0004 0.0004 
% Dose 0.105 - - 0.078 
Serum 1 h 
% Dose/g 0.0040 0.0036 0.0046 - 
Serum 4 h 
% Dose/g 0.0042 0.0036 0.0045 0.0045 
Serum 24 h 
% Dose/g 0.0022 0.0027 0.0034 0.0033 
Serum 48 h 
% Dose/g 0.0022 0.0022 0.0023 0.0026 
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Fig. 2. Scintigraphic depiction 
of the distribution of a31I-PIPA 
in a human subject with carci- 
noid (A-C  24 h post-injection; 
D - F  48 h post-injection). 
A and D anterior chest, B ante- 
rior chest/abdomen, C and F 
anterior abdomen/pelvis, E an- 
terior abdomen of 99mTc-sul- 
phur colloid liver scan showing 
photopenic defects due to me- 
tastases (arrows). (H heart, B 
bladder, L liver) 
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Table 4. Clinical features and scan results of patients studied with 13q_ and 123I-MIBG 
Patient Presentation Site of metastases Results of MIBG scan 
1 Terminal ileum (resected) None 
2 Terminal ileum (resected) Liver: R and L lobes, multiple 
3 Laryngoepiglottic fold None 
(resected) 
4 Terminal ileum (resected) Liver 
5 Small bowel (resected) Both liver lobes 
6 Ovary (resected) None 










Idiopathic flushing syndrome 
Small bowel (resected) 
Idiopathic flushing syndrome 
Unknown primary carcinoid 
Terminal ileum (resected) 
Terminal ileum (resected) 
Ileal polyp (resected) 
Idiopathic flushing syndrome 
Idiopathic flushing syndrome 
Distal ileum 
Flushing, diarrhoea (extensive 
investigations negative) 
None 
Liver and mesentery 
None 
Both lobes of liver 
Pancreatic 




Rising 5-HIAA, enlarging 
nodes on CT 
None 
True-re 
True+ve - 2 large lesions 





True+Ve - masses on CXR 
visualized 
True-ve 
Liver - false -ve; mesenteric 










a Indicates studied with 123I-MIBG; all others with 131I-MIBG 
Fig. 3. Anterior planar images of the chest showing moderate up- 
take of 123MIBG in a carcinoid deposit in the right shoulder (ar- 
row) and anterior left rib (arrowhead) in patient 13 (A). The cor- 
responding image from a contemporaneous 99mTc-MDP bone scan 
is provided for comparison. There is somewhat irregular calcifica- 
tion of the costochondral junctions (B). A second lesion on the 
bone scan in a left anterior rib (arrowhead) is barely visible with 
123I-MIBG. (L liver) 
aged 1, 2 and 3 days later using a large field-of-view 
gamma camera  equipped with a high-energy coll imator 
and interfaced to a dedicated minicomputer .  Multiple 
overlapping planar views of  20 min each were acquired 
f rom skull to pelvis. Thyroid  uptake o f  free 13q-iodide 
was b locked by the administration of  oral iodides for 24 
h prior to and 1 week  fol lowing injection with 131I- 
MIBG.  With 123I-MIBG 10 mCi  (specific activity 10-40  
mCi/mg)  was administered intravenously and the patient 
imaged at 4 and 24 h post-injection, using a general-pur- 
pose coll imator and gamma  camera  and the same views 
and acquisit ion times as for  13q-MIBG. Thyro id  uptake 
of free 123I as iodide was also blocked by administration 
of stable iodide solution. 
Results: 1311- and 1231-MIBG studies 
A m o n g  the 12 patients studied with 131I-MIBG, three of  
the seven patients with known primary or metastatic dis- 
ease had positive 131I-MIBG scans, al though in one o f  
the three patients the 13q-MIBG scan demonstrated 
known mesenteric metastases but failed to localize in he- 
patic metastases seen on CT (see Table 4). Both  patients 
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Table 5. Clinical features and scan results of patients studied with 111in pentetreotid e 
Patient Primary findings Metastatic disease 111in pentetreotid e results 
137 
1 Unknown primary Extensive small bowel False-ve for liver lesions; true 
mesentery and liver +ve for bowel 
2 MEN IIa - recurrent medullary None True-ve 
Ca thyroid 
3 Idiopathic flushing None True-ve 
4 Distal ileum Hepatic metastases True+ve - 2 of larger lesions seen 
A 
Fig. 4. A hepatic carcinoid metastasis (arrow) in patient 4 (Table 
5) adjacent to the right kidney is identified by 111in_pentetreotid e 
scanning on the planar posterior images of the upper abdomen 
(A). This lesion was more clearly seen (arrow) on representative 
transverse (not shown) and coronal (C) sections from single-pho- 
?:;/ 
B C 
ton emission tomography of the region. A second lesion (arrow- 
head) in the anterior right lobe of liver is also apparent on a high- 
er section on transverse tomography (B). (S spleen, K kidney, L 
liver) 
with clinical evidence of locally recurrent disease had 
negative scans, as did the patient in whom the primary 
tumour was considered completely resected. The two pa- 
tients with idiopathic flushing syndrome also had nega- 
tive scans. 
In the six patients studied with 123I-MIBG the results 
were as follows: In the patient with recurrent carcinoid, 
no abnormal uptake was evident in the involved para- 
aortic lymph nodes. Moderate uptake of tracer at best 
was seen in only some of the tumor deposits in the pa- 
tient with distant metastatic disease (Fig. 3). The three 
patients diagnosed with idiopathic flushing syndrome af- 
ter extensive investigation and the single patient with 
complete resection of an isolated primary tumour all 
yielded negative studies. 
Materials and methods: H l ln-pentetreotide studies 
As l~lIn-penetreotide has only very recently been ap- 
proved in the United States for the scintigraphic local- 
ization of carcinoid, our experience is limited. Neverthe- 
less, we consider it important to compare and contrast 
results with this third approach to the scintigraphic de- 
piction of carcinoid tumors with those with 131I-PIPA 
and 131I- and 123I-MIBG. Because of the temporal differ- 
ences in the availability of the radiopharmaceuticals, di- 
rect comparisons and not possible. Four patients with 
suspected or confirmed carcinoid tumour were studied: 
two with histological and biochemical proof of tumour 
presence, one after complete resection of a primary car- 
cinoid, and a fourth with an idiopathic flushing syn- 
drome (Table 5). None had received treatment with oct- 
reotide, or recent chemo- or radiotherapy. All were 
scanned with a modern dual-head gamma camera at 4, 
24 and 48 h after the intravenous injection of 6 mCi of 
llqn-pentetreotide. Conjugate whole-body images (8 
cm/min) were acquired at 4 h, with overlapping planar 
views (15 min each) of the trunk at 24 h and single-pho- 
ton emission tomography of the upper abdomen. The 
conjugate planar views were repeated at 48 h. Laxatives 
were prescribed prior to imaging at 24 and 48 h, and vig- 
orous hydration encouraged. 
Results: 11qn-pentetreotide studies 
Scintigraphic abnormalities at known sites of disease 
were evident in both patients with documented carcinoid 
tumour (Fig. 4). The studies were normal in the two pa- 
tients in whom anatomical imaging and biochemical 
studies failed to disclose evidence of tumour. 
Discussion 
Historically, attempts to image carcinoid tumours with 
iodinated phenylalanine were followed by the use of 
131I- and 1231-MIBG and, later, 111In-pentetreotide for 
this purpose. It was considered important to document 
the false-negative results with 13q-PIPA in scintigraphy 
of carcinoid turnouts. 
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131I and 123I-MIBG, a radioiodinated arakylguanidine, 
is a physiological analogue of norepinephrine and of 
guanethidine [18]. It has been shown to enter the cells of 
the adrenal medulla by a specific energy-dependent up- 
take mechanism (uptake 1) in which it competes with 
norepinephrine, although the kinetics are not those of 
simple competitive inhibition [6]. Most of the MIBG 
concentrates in the intracellular granule fraction (see 
Fig. 1) [19]. The rationale for using MIBG in the imag- 
ing of carcinoid tumours is that these tumours also con- 
tain neurosecretory granules and are derived from the 
APUD cell line [19, 20]. 
The results of 131MIBG in the imaging of carcinoid 
tumours have been variable in the hands of numerous in- 
vestigators. Fischer et al. first described the use of 131I- 
MIBG for scintigraphy of carcinoid in a patient with he- 
patic metastases, with areas of 13q-MIBG uptake in the 
liver corresponding to photopenic defects in hepatic trac- 
er uptake seen on a technetium-99m phytate liver scan 
[21]. A recent review of the published experience with 
131I-MIBG in carcinoid reported on an aggregate total of 
275 patients from a variety of centres and protocols [6]. 
Of these, 194 patients were considered "true-positives", 
for an overall sensitivity of 70%. In individual series 
40%-100% of the patients with known carcinoid disease 
studied had positive 131MIBG scans. The aggregate re- 
sults should be interpreted cautiously due to dissimilari- 
ties in detection critiera and other parameters between 
individual studies. 
The experience at our institution with 13q-MIBG in 
the imaging of carcinoid tumours has not been as good 
as that of some other investigators. This may in part be 
related to methodology. Although the dose of 0.5 mCi 
131I-MIBG is small, this dose is capable of imaging ap- 
proximately 85% of phaeochromocytmas and is the stan- 
dard approved dose for 13q-MIBG in the USA. Feldman 
et al. appear to have improved the sensitivity of the agent 
by subtracting 99mTc-sulphur colloid liver scans from the 
13q-MIBG images [22]. Both scans were performed 
within a period of a week. From the studies discussed 
above 131I-MIBG would appear to have high specificity 
but only moderate sensitivity in the imaging of carcinoid 
tumours. The experience with 123I-MIBG in carcinoid 
scintigraphy is much more limited, with one group de- 
scribing positive scans (with varying intensity of tracer 
uptake within tumour) in six of seven patients with 
known metastatic disease [23, 24]. Perhaps the relatively 
low specific activity of the radiopharmaceutical (espe- 
cially the 131I-MIBG) played a role in this low sensitivi- 
ty. Highly selected cases of the most MIBG-avid meta- 
static carcinoids may be candidates for experimental 
treatment with large doses of 13q-MIBG. 
For somatostatin receptor scintigraphy initial studies 
utilized 1231- labelled somatostatin analogues, but the 
greatest experience to date is with Hqn-penetetreotide. 
Many other cyclic and linear peptide analogues of so- 
matostain have been synthesized, including 99mTc la- 
belled compounds [25, 26]. Overall sensitivity of in vivo 
carcinoid imaging with l llln-pentetreotide was reported 
as 86% in a recent review of published studies encom- 
passing a total of 451 patients [6]. Similar sensitivities 
have been reported with CT and 11 qn-pentetreotide scin- 
tigraphy in determining the presence or absence of carci- 
noid tumour in patients [27]. However, the subgroups 
detected by the two modalities are not concordant, with 
scintigraphy tending to detect more lesions per patient, 
although histological confirmation of all the scintigraph- 
ic abnormalities as tumour was not always forthcoming. 
Sensitivity for detection of hepatic metastases is much 
greater with CT and ultrasonography than with 111In- 
penetetreotide, which may be attributed to variable up- 
take of tracer within hepatic metastases and the marked 
activity within normal hepatic parenchyma [27]. 
Although early studies classified tissues as being 
"positive" or "negative" for the presence of SSTRs, mo- 
lecular biological techniques have illuminated a more 
complex scenario. Currently five distinct human SSTRs 
(designated SSTR 1-5) have been identified and se- 
quenced (see Fig. 1). These range between 363 and 418 
amino acid residues in size, exhibit considerable se- 
quence identity and are encoded for by genes on differ- 
ent chromosomes [28, 29]. SSTR 1-4 are expressed 
widely, with relative receptor density and proportion 
varying between and within individual tissues [30]. 
SSTR 5 appears predominantly within brain. The vari- 
ous receptor subclasses exhibit differing affinities for the 
endogenous somatostatins and their synthetic analogues. 
Pentetreotide shows high affinity for SSTR 2, less for 
SSTRs 3 and 4, and virtually none for SSTRs 1 and 5 
[29, 31]. The limited SSTR subtyping performed on a 
small number of carcinoids may explain some of the 
false-negative studies. Probes for SSTRs 1-3 revealed 
that tumour expression of SSTR-3 was common (>50%) 
while that of SSTRs 1 and 2 was less frequent [8]. Virtu- 
ally all combinations of receptor expression were ob- 
served, including their total absence. Some of the false- 
negative scintigraphic results with radiolabelled pent- 
etreotide may therefore be explained by tumours ex- 
pressing only receptors which do not bind pentetreotide, 
the low densities of high-affinity receptors (i.e. SSTR 2 
or 3) or no receptors at all. 
Unlike with MIBG and the radiolabelled somatostatin 
analogues, attempts to image carcinoid tumours with 
131I-PIPA were completely unsuccessful despite the ex- 
cellent target-to-background ratio in a relevant animal 
model. While the reason for this difference is not clear, it 
may be related to the underlying physiology of the pos- 
tulated mechanisms of tissue localization of the three 
agents (Fig. 1). MIBG, as previously discussed, is ac- 
tively transported across the cytoplasmic membrane into 
the enterochromaffin tumours cells and subsequently 
stored within intracellular granules. 111In pentetreotide 
binds to the cell surface somatostatin receptors which 
are expressed with considerable frequency and density 
by this tumour type. It has been suggested that a propor- 
tion of the occupied somatostatin receptor complexes 
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may subsequently be internalized, in a fashion analogous 
to a variety of other peptide hormones [6, 32]. PIPA acts 
by binding to and inhibiting tryptophan hydroxylase, the 
rate-limiting enzyme in serotonin synthesis. The 131I- 
PIPA would first have to be transported into the intracel- 
lular compartment before gaining access to tryptophan 
hydroxylase. Rapid enzyme turnover and the high affini- 
ty but low capacity of the enzyme for substrate and the 
intracellular location may in part explain the failure of 
this agent to depict human carcinoid tumours. Enzymes 
characteristically exert powerful metabolic effects even 
when present in minute quantities. The small activity of 
131I-PIPA under these circumstances would provide in- 
sufficient photon flux for imaging. The use of 123I-PIPA 
in larger doses might be contemplated but was not pur- 
sued in light of the completely negative 13q-PIPA stud- 
ies (most phaeochromocytomas and on average 70% of 
carcinoids are satisfactorily imaged with a similar dose 
of ~31I-MIBG). The limited binding capacity of the en- 
zyme contrasts with the potentially large storage capaci- 
ty of the hormonal storage vesicles, or somatostatin re- 
ceptor density. Despite the failure in the case of human 
carcinoid, the general concept of using labelled enzyme 
inhibitors nevertheless remains attractive and potentially 
feasible, as demonstrated by the localization of 1311- 
PIPA in the mouse mastocytoma model and the success- 
ful development of radiolabelled adrenocortical synthe- 
sis inhibitors [33, 34]. 
Conclusion 
One aim of this study was to evaluate the use of radiola- 
belled compounds targeted at the enzymes of the seroto- 
nin synthetic pathway of carcinoid tumours as possible 
imaging agents for these lesions. A competitive inhibitor 
of tryptophan hydroxylase - 131I-P1PA - was synthesized 
and administered to four patients with known metastatic 
carcinoid tumours. In vivo imaging was unsuccessful de- 
spite good tracer targeting in an appropriate animal mod- 
el. It is conceivable that the concentration of enzyme rel- 
ative to tumour bulk was too small to permit imaging. 
Tracing the reuptake and storage of biogenic amines 
with 13II (and probably I23I) MIBG provides a useful but 
imperfect tool for detection of carcinoid tumours with an 
average sensitivity of 70%, and good specificity. This is 
less sensitive than l~lln-pentreotide, which must now be 
considered the radiopharmaceutical of choice. Neverthe- 
less, a selected minority of MIBG-avid carcinoids may 
be treatable with large doses of 131I-MIBG. 
The dense expression of somatostatin receptors by 
most carcinoids has made 111In-pentetreotide scintigra- 
phy the most sensitive current scintigraphic diagnostic 
technique. The scintigraphic demonstration of somato- 
statin receptors may predict the therapeutic response to 
non-radioactive somatostatin analogue therapy. Howev- 
er, even this agent is limited by factors including multi- 
ple sites of prominent upper abdominal physiological 
background activity, relative lack of specificity, and the 
existence of occasional tumours without appropriate re- 
ceptors. 
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